Xcytrin
Active Ingredient(s): Motexafin GadoliniumCategory: Cancer
Xcytrin Overview
Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.[1] History On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.[2] On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3 ...
Read more Xcytrin DetailsDetails May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Motexafin_gadolinium